Affiliation: GlaxoSmithKline Research and Development
- Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorderK Hewett
GlaxoSmithKline, Harlow, UK
J Psychopharmacol 24:521-9. 2010..Adverse events were generally mild to moderate and similar between treatment groups. This study demonstrated that the extended-release bupropion is an effective, well-tolerated treatment for major depression in the elderly...
- Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XRKaren Hewett
GlaxoSmithKline, Pharmaceuticals, New Frontiers Science Park, Harlow, UK
J Psychopharmacol 24:1209-16. 2010..Rates of dry mouth, insomnia and hyperhidrosis were elevated in the bupropion XR group, consistent with its catecholaminergic mechanism...
- Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XRK Hewett
GlaxoSmithKline, New Frontier Science Park, Harlow, UK
J Psychopharmacol 23:531-8. 2009..In this double-blind, placebo-controlled trial, bupropion XR at doses up to 300 mg/day and venlafaxine XR at doses up to 150 mg/day demonstrated comparable antidepressant efficacy...